Kiromic Biopharma Files 8-K Under 'Other Events'
| Field | Detail |
|---|---|
| Company | Kiromic Biopharma, Inc. |
| Form Type | 8-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory-filing
TL;DR
Kiromic Biopharma filed an 8-K for 'Other Events' on 3/11/25. No major news.
AI Summary
Kiromic Biopharma, Inc. filed an 8-K on March 17, 2025, reporting an event that occurred on March 11, 2025. The filing is categorized under 'Other Events' and does not specify any material agreements, asset acquisitions, or executive changes.
Why It Matters
This filing indicates a routine disclosure event for Kiromic Biopharma, with no immediate material impact on its operations or stock value apparent from the filing's category.
Risk Assessment
Risk Level: low — The filing is a standard disclosure under 'Other Events' and does not contain information about significant financial transactions, legal issues, or operational changes that would typically increase risk.
Key Players & Entities
- Kiromic Biopharma, Inc. (company) — Registrant
- March 11, 2025 (date) — Earliest event reported
- March 17, 2025 (date) — Filing date
- 7707 Fannin, Suite 140 Houston, TX, 77054 (address) — Principal executive offices
FAQ
What specific event is Kiromic Biopharma reporting under 'Other Events'?
The filing does not specify the exact nature of the event, only that it falls under the 'Other Events' category.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on March 11, 2025.
What is the filing date of this 8-K for Kiromic Biopharma?
The filing date was March 17, 2025.
What is the principal executive office address for Kiromic Biopharma?
The principal executive office is located at 7707 Fannin, Suite 140 Houston, TX, 77054.
What is the SIC code for Kiromic Biopharma?
The Standard Industrial Classification (SIC) code is 2836 for Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 17, 2025 regarding Kiromic Biopharma, Inc..